Central to energy metabolism within the cell is the enzyme methionine synthase, which is critically dependent upon its co-factor methyl-Co(III)B12. Studies on children with autism have shown an overt deficiency in the activity of methionine synthase in all children studied. Maintenance of methionine synthase activity is critically dependent upon functional vitamin B2 sufficiency (as FMN and FAD), which in turn requires adequate iodine, selenium and molybdenum, and folate. Lack of, or reduced activity of methionine synthase results in reduced production of creatine, melatonin, and acetylcholine, as well as a reduction in products of the sulfation pathway, such as glutathione, iron-sulphur proteins, intracellular processing of iron, and the neurotransmitter hydrogen sulphide. Methionine synthase is irreversibly inactivated by the anaesthetic gas, nitrous oxide, and recent studies strongly suggest that the increased use of nitrous oxide in the birthing suite to provide pain relief has been associated with the dramatic increase in the rate of autism, development delay and ADHD. Of particular concern with nitrous oxide is the finality of the inactivation. Vitamin B12 in the body exists in two distinct pools, the cephalic pool and the extra-cephalic pool. The cephalic pool is “loaded” in utero and once a child is born virtually no vitamin B12 enters the brain for the rest of its life. As a result, inactivation of methionine synthase through the use of nitrous oxide during birthing causes long term irreversible damage to the brain of the foetus, thus leading to irreversible developmental delay. This is in stark contrast to children who have functional vitamin B2/B12 deficiency due to deficiencies in Iodine, Selenium and/or Molybdenum, in which the delay is potentially reversible using the RnB™ protocol.

Dr Gregory Russell-Jones has over 40 years of experience in scientific research, with extensive experience in the in the fields of drug delivery, tumour targeting with vitamins, and various aspects of vitamin B12 biology and biochemistry, including cloning of Intrinsic Factor, the use of vitamin B12 as an oral targeting agent and its use in cancer detection, imaging, and biodistribution. Recently his work has turned to the study of the cause of conditions such as depression, Chronic Fatigue Syndrome and more recently Developmental Delay – autism. These studies have enabled him to identify the mechanism behind Paradoxical B12 deficiency, and the role that functional vitamin B12 deficiency has in the aetiology of depression, chronic fatigue syndrome, and in autism. This work has culminated in the RnB™ protocol currently used in the resolution of chronic fatigue syndrome, autism and dementia. His work has resulted in numerous presentations in local and international meetings, the invention of over 45 patents, and the writing of over 65 peer-reviewed publications of which twelve are related to the biochemistry of autism. He currently is director of B12 Oils Pty Ltd, a company specializing in the topical delivery of high dose vitamin B12 for use in the treatment of the above conditions, and the analysis and interpretation of data used for the study of conditions such as CFS, ASD, AD and PD.